ArticleResearch square2023
Low-cost augmented reality goggles enable precision fluorescence-guided cancer surgery.
Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
4 authors.
Funding
Abstract
Disparities in surgical outcomes often result from subjective than objective decisions dictated by surgical training, experience, and available resources. To improve outcomes, surgeons have adopted advancements in robotics, endoscopy, and intra-operative imaging including fluorescence-guided surgery (FGS), which highlight tumors in real-time without using ionizing radiation. However, like many medical innovations, technical, economic, and logistic challenges have hindered widespread adoption of FGS beyond high-resource centers. To overcome these impediments, we developed the fully-wearable and battery-powered fluorescence imaging augmented reality Raspberry Pi-based goggle system (FAR-Pi). Novel device design ensures distance-independent coalignment between real and augmented FAR-Pi views and offers higher spatial resolution, depth of focus, and fluorescence detection sensitivity than existing bulkier, pricier, and wall-powered technologies. When paired with pan-tumor targeting fluorescent agents such as LS301, FAR-Pi objectively identifies tumors in vivo. As an open-source, affordable, and adaptable system, FAR-Pi is poised to democratize access to FGS and improve health outcomes worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.